Insulin B (20-30)
Code | Size | Price |
---|
TAR-T24168-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24168-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Insulin B (20-30) is a peptide hormone produced by beta cells of the pancreatic islets, and it is considered to be the main anabolic hormone of the body. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells.
CAS:
91921-56-1
Molecular Weight:
1272.41
Purity:
0.98
SMILES:
C([C@@H](NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=CC=C3)NC(CNC([C@@H](NC([C@@H](NC(CN)=O)CCC(O)=O)=O)CCCNC(=N)N)=O)=O)=O)=O)=O)[C@@H](C)O)(=O)N4[C@H](C(N[C@H](C(N[C@H](C(O)=O)C)=O)CCCCN)=O)CCC4
References
Fedewa MV, Hathaway ED, Higgins S, Forehand RL, Schmidt MD, Evans EM. Moderate, but not vigorous, intensity exercise training reduces C-reactive protein. Acta Cardiol. 2017 Aug 28:1-8. doi: 10.1080/00015385.2017.1364832. [Epub ahead of print] PubMed PMID: 28847205.
Guo F, Huang D, Zhang W, Yan Q, Yang Q, Yang Y, Li H, Yun J, Hong W, Yang G. Star-shaped polyester-based elastomers as an implantable delivery system for insulin: Development, pharmacokinetics, pharmacodynamics, and biocompatibility. Mater Sci Eng C Mater Biol Appl. 2018 Mar 1;84:180-187. doi: 10.1016/j.msec.2017.11.045. Epub 2017 Dec 2. PubMed PMID: 29519427.
Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsb?ll T, Holst JJ, Rosenkilde MM, Knop FK. GIP(3-30)NH(2) is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25. PubMed PMID: 28948296.
Meriga B, Parim B, Chunduri VR, Naik RR, Nemani H, Suresh P, Ganapathy S, Vvu SB. Antiobesity potential of Piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats. Nutr Metab (Lond). 2017 Nov 16;14:72. doi: 10.1186/s12986-017-0228-9. eCollection 2017. Erratum in: Nutr Metab (Lond). 2017 Dec 6;14 :76. PubMed PMID: 29176994; PubMed Central PMCID: PMC5693419.